Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
13 déc. 2023 07h30 HE
|
Ocugen
MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
01 déc. 2022 07h30 HE
|
Cognition Therapeutics, Inc.
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting...
Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration
25 avr. 2022 16h01 HE
|
Cognition Therapeutics, Inc.
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the...
Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight
10 févr. 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Dry Age-related Macular Degeneration Pipeline Landscape Analysis by DelveInsight For patients with advanced Dry Age-Related Macular...
Positive Results from Studies of Retrotope’s RT011 in Animal Models of Retinal Degeneration to be Featured in Oral Presentations at 2nd Annual Dry AMD Therapeutic Development Summit
19 oct. 2021 07h00 HE
|
Retrotope
Data Demonstrate RT011 Offers Dose-Dependent Protection Against Retinal Lipid Peroxidation (LPO) and Cell Damage, as well as Preservation of Visual Function Findings Provide Rationale for Advancement...
Achillion Initiates Phase 1 Study of ACH-4471, First Orally-Administered Small Molecule Complement Factor D Inhibitor
11 févr. 2016 06h05 HE
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced the initiation of a phase 1 study with ACH-4471, the Company’s first...